Brief: Gensight Biologics To Submit LUMEVOQ For European Authorization In September
July 21 (Reuters) - GENSIGHT BIOLOGICS SA SIGHT.PA :
* LUMEVOQ ON TRACK FOR SEPTEMBER 2020 SUBMISSION IN EUROPE
Source text for Eikon: ID:nBw1Wl0bCa
Further company coverage: SIGHT.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Gensight Biologics SA
See all newsHealth Rounds: Blindness treatment based on Nobel-winning research shows promise
France's GenSight Biologics H1 net loss widens on higher R&D expenses
Brief: GenSight Biologics H1 Net Income EUR -10.3 Million
France's GenSight Biologics 2025 net loss narrows on reduced R&D spending
Brief: GenSight Biologics FY EPS EUR -0.08